Literature DB >> 8779122

Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes.

R L Souhami.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8779122      PMCID： PMC1090630          DOI： 10.1136/thx.51.3.231

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  8 in total

Review 1.  Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.

Authors:  R C Lilenbaum; M R Green
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

2.  Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer.

Authors:  D C Currie; D W Miles; J S Drake; R Rudd; S G Spiro; H M Earl; P G Harper; J S Tobias; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

4.  Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.

Authors:  K M Pisters; M G Kris; R J Gralla; M B Zaman; R T Heelan; N Martini
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

5.  International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA.

Authors:  D L Davis; D Hoel; J Fox; A Lopez
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

6.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

Authors:  T Le Chevalier; D Brisgand; J Y Douillard; J L Pujol; V Alberola; A Monnier; A Riviere; P Lianes; P Chomy; S Cigolari
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

Review 7.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

8.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.